Our approach might represent an alternative to Imura’s product, displaying an easier manufacturing and a greater flexibility, being employable with either bona fide Tregs or CD4+ Tconvs, potentially improving the scalability in clinical settings where autoimmune patients’ lymphopenia might be a limit. Here, CD4 is linked to lymphopenia.